Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30988 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Maximilian Klink und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, University of Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Anemia, Sickle Cell, beta-Thalassemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitat Zurich.
Abstract (Originalsprache)
Background
Hematopoietic cell transplantation (HCT) is an established curative therapy for transfusion‐dependent thalassemia (TDT) and sickle cell disease (SCD). The latest American Society of Hematology guidelines recommend myeloablative preparative regimen in patients under 18 years of age. Procedure The objective was to demonstrate safety and efficacy of a reduced intensity conditioning (RIC) regimen including high‐dose fludarabine, anti‐thymocyte globulin, and targeted busulfan as a single alkylator to sub‐myeloablative exposures.
Results
Between 2012 and 2021, 11 patients with SCD and five patients with TDT and matched related donor (MRD) HCT were included. The median age at transplantation was 8.3 years (range: 3.7–18.8 years). The median administered busulfan AUC was 67.4 mg/L×h (range: 60.7–80 mg/L×h). Overall survival was 93.8% and event‐free survival 87.5% with one engrafted SCD patient with pre‐existing moyamoya disease succumbing after drainage of a subdural hematoma. One SCD patient developed a secondary graft failure and was treated with a second HCT. Myeloid chimerism was full in all other patients with a median follow‐up time of 4.1 years (range: 2.0–11.1 years), whereas T‐cell donor chimerism was frequently mixed.
Conclusion
This RIC conditioning followed by MRD HCT is sufficiently myeloablative to cure pediatric patients with hemoglobinopathies without the need for additional total body irradiation or thiotepa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty, University of Zürich, Zürich, Switzerland.
- Division of Stem Cell Transplantation and Children's Research Center, University Children's Hospital Zurich, University of Zürich, Zürich, Switzerland.
- Division of Hematology and Children's Research Center, University Children's Hospital Zurich, University of Zürich, Zürich, Switzerland.
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kantonsspital Aarau, Aarau, Switzerland.
ORCID-Profile: Daniel Drozdov, Tayfun Güngör
Förderung
- Universitat Zurich
Zitieren
APA
Klink, M., Felber, M., Zeilhofer, U., Hauri-Hohl, M., Schmugge, M., Drozdov, D., & Güngör, T. (2024). Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30988
Vancouver
Klink M, Felber M, Zeilhofer U, Hauri-Hohl M, Schmugge M, Drozdov D, et al. Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30988
BibTeX
@article{Klink2024,
author = {Klink, Maximilian and Felber, Matthias and Zeilhofer, Ulrike and Hauri-Hohl, Mathias and Schmugge, Markus and Drozdov, Daniel and Güngör, Tayfun},
title = {Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30988}
}
EUVIMED